Ascentage Pharma (6855.HK), a pioneering biopharmaceutical company revolutionizing the way cancer, chronic hepatitis B (CHB), and age-related diseases are treated, is thrilled to announce that its Chairman and CEO, Dr. Dajun Yang, has been invited to speak at the highly-regarded 41st Annual J.P. Morgan Healthcare Conference. On January 11, 2023, at 8:30 AM Pacific Time (00:30 AM Beijing Time), Dr. Yang will provide an update on Ascentage Pharma’s cutting-edge research and development initiatives. Don’t miss this exciting opportunity to learn about the progress of this revolutionary company!
The highly anticipated 41st J.P. Morgan Healthcare Conference is back and ready to wow the global pharmaceutical industry and the investment community! Taking place in San Francisco, California, this exceptional four-day event will be packed with informative talks and discussions on the latest industry trends and developments. Don’t miss the chance to take part in the largest and most influential event of its kind – book your tickets now!
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, invites you to join him for an engaging conversation about the future of the pharmaceutical industry on January 11th at 8:30-8:55 AM (Pacific Time) / January 12th, 00:30-00:55 AM (Beijing Time). Don’t miss out on this unique opportunity to gain valuable insights from one of the most influential industry leaders!
About Ascentage Pharma
Ascentage Pharma is leading the charge in developing innovative therapeutics that target protein-protein interactions and restore apoptosis, or programmed cell death. With an impressive pipeline of nine clinical drug candidates and over 50 phase 1/2 clinical trials in the US, Australia, Europe, and China, they are at the forefront of a revolution in medical treatments. Ascentage Pharma is the only company with active clinical programs targeting all three known classes of key apoptosis regulators, and has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases. With this cutting-edge research and development, Ascentage Pharma is paving the way for revolutionary treatments that could save countless lives.
Ascentage Pharma is a pioneering biopharmaceutical company that is making strides in the field of apoptosis restoration. With a pipeline of 9 clinical drug candidates, their research is focused on inhibiting protein-protein interactions. Ascentage is the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators, including novel, highly potent Bcl-2, dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). They are conducting over 50 phase 1/2 clinical trials in various countries, and have been recognised for their innovative research with multiple Major National R&D Projects. It is clear that Ascentage Pharma is leading the way in the development of therapeutics to restore apoptosis.
Ascentage Pharma is paving the way for groundbreaking treatments for drug-resistant chronic myeloid leukemia (CML) with its core drug candidate olverembatinib. The US FDA has granted the company an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) for the drug, while the EMA of the EU has granted it an Orphan Designation. Furthermore, the Center for Drug Evaluation (CDE) in China has granted a priority review status and a Breakthrough Therapy Designation (BTD) to the New Drug Application (NDA) submitted for HQP1351. In total, Ascentage Pharma has obtained 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for its four investigational drug candidates, making it a leader in the field of CML treatments.
Ascentage Pharma is dedicated to fulfilling its mission of addressing unmet clinical needs in China and around the world, and is leveraging its robust R&D capabilities to do so. The company has amassed a portfolio of global intellectual property rights, entered into partnerships with renowned biotechnology and pharmaceutical companies and research institutes, and is building a talented team with global experience to develop innovative drugs. Additionally, Ascentage Pharma is setting up its world-class commercial manufacturing and Sales & Marketing teams to accelerate its clinical development programs and better serve patients in need.
Forward-Looking Statements
Looking ahead, Ascentage Pharma is committed to taking the necessary steps to ensure a bright future. We recognize that our plans may change over time and we are prepared to adjust our strategies to reflect the changing landscape. With that in mind, we invite you to join us on our journey and share in our optimism as we strive to achieve our goals. Our team is dedicated to staying up-to-date with the latest advancements, so that we can ensure the best possible outcomes for all involved. Let’s take this opportunity to build something great.